Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

被引：0
|
作者：
N. I. Bouwer
T. G. Steenbruggen
J. van Rosmalen
H. N. Rier
J. J. E. M. Kitzen
M. L. van Bekkum
A. J. Ten Tije
P. C. de Jong
J. C. Drooger
C. Holterhues
C. H. Smorenburg
M. J. M. Kofflard
E. Boersma
G. S. Sonke
M.-D. Levin
A. Jager
机构：
[1] Albert Schweitzer Hospital,Department of Internal Medicine
[2] Albert Schweitzer Hospital,Department of Cardiology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] Erasmus MC,Department of Biostatistics
[5] University Medical Centre Rotterdam,Department of Medical Oncology
[6] Erasmus MC,Department of Medical Oncology
[7] Cancer Institute,Department of Medical Oncology
[8] Reinier de Graaf Hospital,Department of Medical Oncology
[9] Amphia Hospital,Department of Medical Oncology
[10] Sint Antonius Hospital,Department of Medical Oncology
[11] Ikazia Hospital,Department of Cardiology
[12] Haga Hospital,undefined
[13] Erasmus MC,undefined
[14] University Medical Centre Rotterdam,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
HER2-positive metastatic breast cancer; Trastuzumab treatment; Cardiotoxicity; LVEF monitoring; Screening for cardiotoxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：851 / 862
页数：11
相关论文
共 50 条
  • [21] Cardiotoxicity in HER2-positive breast cancer patients
    Diana Gonciar
    Lucian Mocan
    Alexandru Zlibut
    Teodora Mocan
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 919 - 935
  • [22] Long-term results on trastuzumab (T) in elderly patients (EP) with locally advanced or metastatic HER2-positive breast cancer (BC).
    Jackisch, Christian
    Schoenegg, Winfried
    Reichert, Dietmar Arno
    Welslau, Manfred
    Selbach, Johannes
    Harich, Hanns-Detlev
    Tesch, Hans
    Wohlfarth, Tim
    Eustermann, Heidi
    Hinke, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
  • [24] Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer
    Calvillo-Arguelles, Oscar
    Abdel-Qadir, Husam
    Suntheralingam, Sivisan
    Michalowska, Maria
    Amir, Eitan
    Thavendiranathan, Paaladinesh
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (08): : 1270 - 1275
  • [25] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Murthy, Pooja
    Kidwell, Kelley M.
    Schott, Anne F.
    Merajver, Sofia D.
    Griggs, Jennifer J.
    Smerage, Jeffrey D.
    Van Poznak, Catherine H.
    Wicha, Max S.
    Hayes, Daniel F.
    Henry, N. Lynn
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 589 - 595
  • [26] Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
    Pooja Murthy
    Kelley M. Kidwell
    Anne F. Schott
    Sofia D. Merajver
    Jennifer J. Griggs
    Jeffrey D. Smerage
    Catherine H. Van Poznak
    Max S. Wicha
    Daniel F. Hayes
    N. Lynn Henry
    Breast Cancer Research and Treatment, 2016, 155 : 589 - 595
  • [27] Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
    Daniel Eiger
    Noam F. Pondé
    Dominique Agbor-Tarh
    Alvaro Moreno-Aspitia
    Martine Piccart
    Florentine S. Hilbers
    Olena Werner
    Saranya Chumsri
    Amylou Dueck
    Judith R. Kroep
    Henry Gomez
    István Láng
    Richard J. Rodeheffer
    Michael S. Ewer
    Thomas Suter
    Evandro de Azambuja
    British Journal of Cancer, 2020, 122 : 1453 - 1460
  • [28] Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
    Eiger, Daniel
    Ponde, Noam F.
    Agbor-Tarh, Dominique
    Moreno-Aspitia, Alvaro
    Piccart, Martine
    Hilbers, Florentine S.
    Werner, Olena
    Chumsri, Saranya
    Dueck, Amylou
    Kroep, Judith R.
    Gomez, Henry
    Lang, Istvan
    Rodeheffer, Richard J.
    Ewer, Michael S.
    Suter, Thomas
    de Azambuja, Evandro
    BRITISH JOURNAL OF CANCER, 2020, 122 (10) : 1453 - 1460
  • [29] Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.
    Schiavone, Andrea
    Diaz, Mariana
    Camejo, Natalia
    Reborido, Natalia
    Vazquez, Horacio
    Parma, Gabriel
    Vazquez, Alvaro
    Castillo, Cecilia
    Krygier, Gabriel David
    Delgado, Lucia Beatriz
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [30] Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
    Muhammet Ali Kaplan
    Hamza Ertugrul
    Ugur Firat
    Mehmet Kucukoner
    Ali İnal
    Zuhat Urakci
    Zafer Pekkolay
    Abdurrahman Isikdogan
    Breast Cancer, 2015, 22 : 503 - 509
12345